Autoimmune diseases, Dermatitis, Dermatological disorders, Psoriasis
Watch Time: 5 mins

William Damsky, Dermatology Meeting News 2023: A personalised approach to treating inflammatory skin diseases
Recent content from our partner site touchIMMUNOLOGY

Copy Link
Published Online: Oct 11th 2023

Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, USA) around the recent advances made in biomarkers and targeted therapies for inflammatory skin diseases, how a personalised approach will improve patient outcomes and quality-of-life and the future of personalised medicine in dermatology.

The abstract ‘Personalized medicine approaches to select the best treatment for patients with inflammatory skin diseases.’ was presented at AAD 2023, 17-21 March, 2023.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.  


  1. What recent advances have been made in biomarkers and targeted therapies for inflammatory skin diseases? (0:13)
  2. How will a personalised approach to treatment improve patient outcomes and quality-of-life? (3:06)
  3. What do you consider the future direction of personalised medicine in dermatology? (4:12)

Disclosures: William Damsky discloses consulting for: Pfizer, Incyte, Eli Lilly, TWI Biotechnology, Fresenius Kabi, Epiarx Diagnostics, and Boehringer Ingelheim; receiving grant/research support from: Pfizer, Advanced Cell Diagnostics/Bio-Techne, AbbVie, Bristol Myers Squibb, and Incyte; and receiving licensing fees from: EMD/Millipore/Sigma.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the 2023 AAD Annual Meeting.

Click here for more content on dermatological conditions.


What recent advances have been made in biomarkers and targeted therapies for inflammatory skin diseases? (0:13)

So people are really starting to think about this, which is exciting and so we’ve done some work in this area and there’s others that have done work in this area and so really the idea is what approach can be used to, you know, again, bridge this gap? How do we really decipher the immunology of any individual patient to pick the best therapy for them right out of the gate? And so what our group has employed is a cytokine staining approach and so we use an RNA in situ hybridization strategy, and we selected that because it’s very specific and appears to work very well and really rationally asking the question, what is the predominant cytokine or group of cytokines that’s expressed in a skin disease? So, we recently published a paper which is in the JAAD in atopic dermatitis and we said, you know what proportion of patients express in their atopic dermatitis only IL-13 or IL-4 and what percentage of patients also express other cytokines in addition, like interferon gamma, like a type 1 immune response or IL-17, a type 3 immune response. And what we found is that patients and this is a cohort of patients treated with dupilumab, which blocks the IL-4 receptor alpha, so it inhibits IL-4 and IL-13, we asked what percent or what were the cytokine profiles like in patients that responded well versus suboptimal lead to dupilumab? What we found is that the patients with the best responses to dupilumab expressed more sort of a pure IL-4 IL-13 profile which is targeted by the drug. In those patients that didn’t do quite as well, expressed other noncanonical cytokines like interferon gamma and IL-17 and so to us that was a really exciting finding and sort of provided some proof of concept that this was a viable approach to, to sort of dissect the immunologic heterogeneity in atopic dermatitis, for example. But I think these principles can be applied to other inflammatory skin diseases. There’s a couple other companies that are interested in this so Mindera is a company that’s developed sort of this biomarker patch which looks at RNA expression in lesions of psoriasis, and now based on an algorithm they developed to recommend optimal therapy for patients. I know CAS Biosciences is interested in this as well, and they’re using curettage as a method to collect tissue for analysis. Others are looking at tape stripping. And so really, it’s an exciting time in this area because there’s a lot of people thinking about it and trying to decide the best way to do this.

How will a personalised approach to treatment improve patient outcomes and quality-of-life? (3:06)

So, I think really the advantage here and we’re not there yet, but the goal is that the patient ends up on optimal therapy right out of the gate. And so it’s not uncommon to have a patient with psoriasis, for example, that may be treated with a medication like a TNF alpha inhibitor or maybe, you know, an IL-12 -23 inhibitor that has sort of a suboptimal response, but a response and sometimes these patients remain on that therapy when there may be another medicine like an IL-23 specific inhibitor out there that might clear their skin. And so I think it really gives hopefully will give us the ability to just put the patient on the optimal drug right from the get go, which will make life easier for patients, but make life easier for staff in the office that are going through great efforts to get these medications covered for patients. And we’re really just generally improve the efficiency of treatment of these disorders.

What do you consider the future direction of personalised medicine in dermatology? (4:12)

I think the ability to stratify patients with a similar with the same diagnosis into different groups. So let’s take briefly the example of atopic dermatitis. We might think about grouping patients into IL-13, predominantly atopic dermatitis versus sort of mixed atopic dermatitis where there may be more IL-17 or IL-22 interferon gamma. And we may even move beyond, you know, sort of a morphologic diagnosis and think about diagnoses like IL-13 predominant papulosquamous payments disorder that may not fit into any sort of specific category, but where the immunology sort of dictates what the patient is likely to respond to. So I think the future is, you know, subclassifying patients with the same diagnosis into therapeutically relevant categories. So it’s an exciting time.

Subtitles and transcript are autogenerated.

Related Videos In Psoriasis
Knut Schakel EADV 2023
Developed by Touch
GUIDE phase 3b findings – maintaining response following guselkumab withdrawal in psoriasis: Knut Schäkel
Watch Time: 5 mins

GUIDE is a phase 3b randomized, parallel-group, double-blind trial investigating guselkumab for the treatment of moderate-to-severe psoriasis (NCT03818035). We were delighted to speak with Prof. Knut Schäkel (University Hospital Heidelberg, Germany) to discuss the clinical data already supporting GUS from GUIDE 1 and 2, and the rationale, methodology and findings from GUIDE part 3, which were presented at EADV. The abstract 'Treatment-free period of more than 1 year in guselkumab super responders with short disease duration of psoriasis: withdrawal data from the GUIDE trial' (Abstract N°: 2042) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What were the aims, design and eligibility criteria of the Phase 3b GUIDE trial? (0:16) What data from GUIDE 1 and 2 already supports early intervention with GUS? (1:28) Could you describe the rationale and methodology of GUIDE part 3? (2:19) What were the clinical endpoints and how well were these achieved? (3:10) What significance do these findings have in terms of maintenance of response following GUS withdrawal? (4:06) Disclosures: Knut Schäkel has been an advisor and/ or received speakers' honoraria and/ or received grants and/ or participated in clinical trials of the following companies: AbbVie, Almirall, Antabio, Boehringer Ingelheim, Celgene, Eli Lily, Galderma, Janssen-Cilag GmbH, LEO Pharma, Novartis, Pfizer and UCB Pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.  Click here for more content on psoriasis & for further EADV 2023 highlights visit here.

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72